跳至主要内容
临床试验/JPRN-UMIN000041205
JPRN-UMIN000041205
已完成
未知

A retrospective study to evaluate the predictive ability of a DNA methylation status-based diagnostic method for the sensitivity of anti-EGFR treatment in metastatic colorectal cancer - Observational study on a method for predicting the efficacy of anti-EGFR treatment for colorectal cancer

Institute of Development, Aging and Cancer (IDAC), Tohoku University0 个研究点目标入组 241 人2020年7月24日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Metastatic colorectal cancer
发起方
Institute of Development, Aging and Cancer (IDAC), Tohoku University
入组人数
241
状态
已完成
最后更新
2年前

概览

简要总结

DNA methylation status may be a predictor of therapeutic response to anti-EGFR antibody drugs in the first-line treatment of metastatic colorectal cancer.

注册库
who.int
开始日期
2020年7月24日
结束日期
2021年3月31日
最后更新
2年前
研究类型
Observational
性别
All

研究者

发起方
Institute of Development, Aging and Cancer (IDAC), Tohoku University

入排标准

入选标准

  • 未提供

排除标准

  • Patients who received anti\-EGFR antibodies in the first or second line of treatment. Cases in which the patient is unable to submit the required amount of tissue samples from the primary tumor for measurement of methylation status. Cases considered by the attending physician to be unsuitable for enrollment in this study.

结局指标

主要结局

未指定

相似试验